The Role of Thrombophilia in Splanchnic Vein Thrombosis

ABSTRACT

In the last few years, the mechanistic role of thrombophilia due to hypercoagulability and of clonal disorders of hemopoiesis such as chromosome Philadelphia-negative chronic myeloproliferative disorders has been increasingly recognized in primary splanchnic vein thrombosis. As in deep venous thrombosis of the lower limbs, the frequent finding of several prothrombotic disorders in the same individual has led to the concept of primary splanchnic vein thrombosis as a multifactorial disease. Significant progress has been made in determining the molecular bases of inherited thrombophilia, and particularly in the identification of molecular markers of clonal disease in the so-called occult or latent myeloproliferative disorders. In this review article, the authors discuss the current knowledge on the role of thrombophilia in extrahepatic portal vein obstruction and in the Budd–Chiari syndrome, two of the most clinically relevant splanchnic vein thromboses.

KEYWORDS

Thrombophilia - hypercoagulability - splanchnic vein thrombosis - myeloproliferative disorders

REFERENCES

• 1 Janssen H L, Garcia-Pagan J C, Elias E, Mentha G, Hadengue A, Valla D C. Budd-Chiari syndrome: a review by an expert panel.  J Hepatol. 2003;  38 364-371
• 2 Janssen H L, Meinardi J R, Vleggaar F P et al.. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study.  Blood. 2000;  96 2364-2368
• 3 Denninger M H, Chait Y, Casadevall N et al.. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors.  Hepatology. 2000;  31 587-591
• 4 Mahmoud A E, Mendoza A, Meshokhes A N et al.. Clinical spectrum, investigations and treatment of Budd-Chiari syndrome.  QJM. 1996;  89 37-43
• 5 Rosenberg R D, Aird W C. Vascular-bed-specific hemostasis and hypercoagulable states.  N Engl J Med. 1999;  340 1555-1564
• 6 Rosendaal F R. Venous thrombosis: a multicausal disease.  Lancet. 1999;  353 1167-1173
• 7 Schafer A I. Hypercoagulable states: molecular genetics to clinical practice.  Lancet. 1994;  344 1739-1742
• 8 Deltenre P, Denninger M H, Hillaire S et al.. Factor V Leiden related Budd-Chiari syndrome.  Gut. 2001;  48 264-268
• 9 Okuda H, Yamagata H, Obata H et al.. Epidemiological and clinical features of Budd-Chiari syndrome in Japan.  J Hepatol. 1995;  22 1-9
• 10 Valla D. Hepatic venous outflow tract obstruction etiopathogenesis: Asia versus the West.  J Gastroenterol Hepatol. 2004;  19 S204-S211
• 11 Shrestha S M, Okuda K, Uchida T et al.. Endemicity and clinical picture of liver disease due to obstruction of the hepatic portion of the inferior vena cava in Nepal.  J Gastroenterol Hepatol. 1996;  11 170-179
• 12 Sarin S K, Agarwal S R. Extrahepatic portal vein obstruction.  Semin Liver Dis. 2002;  22 43-58
• 13 Valla D C. Hepatic vein thrombosis (Budd-Chiari syndrome).  Semin Liver Dis. 2002;  22 5-14
• 14 Kamphuisen P W, Eikenboom J C, Bertina R M. Elevated factor VIII levels and the risk of thrombosis.  Arterioscler Thromb Vasc Biol. 2001;  21 731-738
• 15 Lane D A, Bayston T, Olds R J et al.. Antithrombin mutation database: 2^nd (1977) update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.  Thromb Haemost. 1997;  77 197-211
• 16 McClure S, Dincsoy H P, Glueck H. Budd-Chiari syndrome and antithrombin III deficiency.  Am J Clin Pathol. 1982;  78 236-241
• 17 Das M, Carroll S F. Antithrombin III deficiency: an etiology of Budd-Chiari syndrome.  Surgery. 1985;  97(2) 242-246
• 18 Mohanty D, Shetty S, Ghosh K, Pawar A, Abraham P. Hereditary thrombophilia as a cause of Budd-Chiari syndrome: a study from Western India.  Hepatology. 2001;  34 666-670
• 19 Kalafatis M, Rand M D, Mann KgG. The mechanism of inactivation of human factor V and human factor Va by activated protein C.  J Biol Chem. 1994;  269 31869-31880
• 20 Griffin J H, Evatt B, Zimmermann T et al.. Deficiency of protein C in congenital thrombotic disease.  J Clin Invest. 1981;  68 1370-1373
• 21 Schwarz H P, Fischer M, Hopmeier P et al.. Plasma protein S deficiency in familial thrombotic disease.  Blood. 1984;  64 1297-1300
• 22 Comp P C, Esmon C T. Recurrent venous thromboembolism in patients with a partial deficiency of protein S.  N Engl J Med. 1984;  311 1525-1528
• 23 Branson H E, Katz J, Marble R et al.. Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn infant.  Lancet. 1983;  2 1165-1168
• 24 Mahasandana C, Suvatte V, Marlar R A et al.. Neonatal purpura fulminans associated with homozygous protein S deficiency.  Lancet. 1990;  335 61-62
• 25 Egesel T, Buyukasik Y, Dundar S V et al.. The role of natural anticoagulant deficiencies and Factor V Leiden in the development of idiopathic portal vein thrombosis.  J Clin Gastroenterol. 2000;  30 66-71
• 26 Primignani M, Martinelli I, Bucciarelli P et al.. Risk factors for thrombophilia in extrahepatic portal vein obstruction.  Hepatology. 2005;  41 603-608
• 27 Kalafatis M, Bertina R M, Rand M D et al.. Characterization of the molecular defect in factor V R506Q.  J Biol Chem. 1995;  270 4053-4057
• 28 Price D T, Ridker P M. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective.  Ann Intern Med. 1997;  127 895-903
• 29 Bombeli T, Basic A, Fehr J. Prevalence of hereditary thrombophilia in patients with thrombosis in different venous systems.  Am J Hematol. 2002;  70 126-132
• 30 Mahmoud A E, Wilde J T, Elias E. Budd-Chiari syndrome and factor V Leiden mutation.  Lancet. 1995;  345(8948) 526
• 31 Denninger M H, Helley D, Valla D et al.. Prospective evaluation of the prevalence of Factor V Leiden mutation in portal or hepatic vein thrombosis.  Thromb Haemost. 1997;  78 1297-1298
• 32 Chamouard P, Pencreach E, Maloisel F et al.. Frequent factor II G20210A mutation in idiopathic portal vein thrombosis.  Gastroenterology. 1999;  116 144-148
• 33 Mahmoud A EA, Elias E, Beauchamp N et al.. Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis.  Gut. 1997;  40 798-800
• 34 Pearson T C, Messinezy M. The diagnostic criteria of polycythaemia rubra vera.  Leuk Lymphoma. 1996;  22(Suppl 1) 87-93
• 35 Tefferi A, Thiele J, Orazi A et al.. Proposal and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis: recommendations from an ad hoc international expert panel.  Blood. 2007;  110 1092-1097
• 36 Barosi G, Buratti A, Costa A et al.. An atypical myeloproliferative disorder with high thrombotic risk and slow disease progression.  Cancer. 1991;  68 2310-2318
• 37 Hirshberg B, Shouval D, Fibach E, Friedman G, Ben-Yehuda D. Flow cytometric analysis of autonomous growth of erythroid precursors in liquid culture detects occult polycythemia vera in the Budd-Chiari syndrome.  J Hepatol. 2000;  32 574-578
• 38 De Stefano V, Teofili L, Leone G, Michiels J J. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis.  Semin Thromb Hemost. 1997;  23 411-418
• 39 Dayal S, Pati H P, Pande G K, Sharma M P, Saraya A K. Multilineage hemopoietic stem cell defects in Budd Chiari syndrome.  J Hepatol. 1997;  26 293-297
• 40 Chait Y, Condat B, Cazals-hatem D et al.. Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis.  Br J Haematol. 2005;  129 553-560
• 41 Pagliuca A, Mufti G J, Janossa-Tahernia M et al.. In vitro colony culture and chromosomal studies in hepatic and portal vein thrombosis. Possible evidence of an occult myeloproliferative state.  Q J Med. 1990;  76 981-989
• 42 McNamara C, Juneja S, Wolf M et al.. Portal or hepatic vein thrombosis as the first presentation of a myeloproliferative disorder in patients with normal peripheral blood counts.  Clin Lab Haematol. 2002;  24 239-242
• 43 Dudley J M, Westwood N, Leonard S et al.. Primary polycythemia: positive diagnosis using the differential response of primitive and mature erythroid progenitors to erythropoietin, interleukin 3 and alpha-interferon.  Br J Haematol. 1990;  75 188-194
• 44 Dainiak N, Hoffman R, Lebowitz A I et al.. Erythropoietin-dependent primary pure erythrocytosis.  Blood. 1979;  53 1076-1084
• 45 Eridani S, Dudley J M, Sawyer B M et al.. Erythropoietic colonies in a serum-free system: results in primary proliferative polycythemia and thrombocythemias.  Br J Haematol. 1987;  67 387-391
• 46 Vardiman J W, Harris N L, Brunning R D. The World Health Organization (WHO) classification of the myeloid neoplasms.  Blood. 2002;  100 2292-2302
• 47 Georgii A, Buhr T, Buesche G, Kreft A, Choritz H. Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies.  Leuk Lymphoma. 1996;  22(Suppl 1) 15-29
• 48 Thiele J, Kvasnicka H M, Diehl V. Bone marrow features of diagnostic impact in erythrocytosis.  Ann Hematol. 2005;  84 362-367
• 49 Thiele J, Kwasnicka H M. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients.  Ann Hematol. 2003;  82 148-152
• 50 Wilkins B S, Erber W N, Bareford D et al.. Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes.  Blood. 2008;  111 60-67
• 51 Liu E, Jelinek J, Pastoire Y D et al.. Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin.  Blood. 2003;  101 3294-3301
• 52 Moliterno A R, Hankins W D, Spivak J L. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera.  N Engl J Med. 1998;  338 572-580
• 53 Klippel S, Strunck E, Temerinac S et al.. Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis.  Blood. 2003;  102 3569-3574
• 54 Kralovics R, Buser A S, Teo S S et al.. Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders.  Blood. 2003;  102 1869-1971
• 55 James C, Ugo V, Le Couedic J P et al.. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.  Nature. 2005;  434 1144-1148
• 56 Kralovics R, Passamonti F, Buser A S et al.. A gain-of-function mutation of JAK2 in myeloproliferative disorders.  N Engl J Med. 2005;  352 1779-1790
• 57 Baxter E J, Scott L M, Campbell P J et al.. Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.  Lancet. 2005;  365 1054-1061
• 58 Levine R L, Wadleigh M, Cools J et al.. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.  Cancer Cell. 2005;  7 387-397
• 59 Zhao R, Xing S, Li Z et al.. Identification of an acquired JAK2 mutation in polycythemia vera.  J Biol Chem. 2005;  280 22788-22792
• 60 Jones A V, Kreil S, Zoi K et al.. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.  Blood. 2005;  106 2162-2168
• 61 Xu X, Zhang Q, Luo J et al.. JAK2(V617F): Prevalence in a large Chinese hospital population.  Blood. 2007;  109 339-342
• 62 Steensma D P, Dewald G W, Lasho T L et al.. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromes.  Blood. 2005;  106 1207-1209
• 63 Jelinek J, Oki Y, Gharibyan V et al.. JAK2 mutation 1849G> T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia.  Blood. 2005;  106 3370-3373
• 64 Arellano-Rodrigo E, Alvarez-Larran A, Reverter J C et al.. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status.  Haematologica. 2006;  91 169-175
• 65 Cheung B, Radia D, Pantelidis P et al.. The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia.  Br J Haematol. 2006;  132 244-245
• 66 Carobbio A, Finazzi G, Guerini V et al.. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and JAK2 mutation status.  Blood. 2007;  109 2310-2313
• 67 Landolfi R, Di Gennaro L, Barbui T et al.. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera.  Blood. 2007;  109 2446-2452
• 68 Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera.  Exp Hematol. 2005;  33 523-530
• 69 Passamonti F, Rumi E, Pietra D et al.. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34 + cells into peripheral blood in myeloproliferative disorders.  Blood. 2006;  107 3676-3682
• 70 Scott L M, Tong W, Levine R L et al.. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.  N Engl J Med. 2007;  356(5) 459-468
• 71 Pikman Y, Lee B H, Mercher T et al.. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.  PLoS Med. 2006;  3 e270
• 72 Pardanani A D, Levine R L, Lasho T et al.. A. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.  Blood. 2006;  108 3472-3476
• 73 Patel R K, Lea N C, Heneghan M A et al.. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome.  Gastroenterology. 2006;  130 2031-2038
• 74 Primignani M, Barosi G, Bergamaschi G et al.. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis.  Hepatology. 2006;  44 1528-1534
• 75 Colaizzo D, Amitrano L, Tiscia G L, Grandone E, Guardascione M A, Margaglione M. A new JAK2 gene mutation in patients with polycythemia vera and splanchnic vein thrombosis.  Blood. 2007;  110 2768-2769
• 76 Kiladjian J J, Cervantes F, Leebeek F W et al.. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis. A report on 241 cases.  Blood. 2008;  11(10) 4922-4929
• 77 Bergamaschi G, Primignani M, Barosi G et al.. MPL and JAK2 exon 12 mutations in patients with the Budd-Chiari syndrome or extrahepatic portal vein obstruction.  Blood. 2008;  111 4418
• 78 Oelschlaegel U, Besson I, Arnoulet C et al.. A standardized flow cytometric method for screening paroxysmal nocturnal haemoglobinuria (PNH) measuring CD55 and CD59 expression on erythrocytes and granulocytes.  Clin Lab Haematol. 2001;  23 81-90
• 79 Hillmen P, Lewis S M, Bessler M et al.. Natural history of paroxysmal nocturnal hemoglobinuria.  N Engl J Med. 1995;  333 1253-1258
• 80 Socie G, Mary J Y, de Gramont A et al.. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology.  Lancet. 1996;  348 573-577
• 81 Valla D, Dhumeaux D, Babany G et al.. Hepatic vein thrombosis in paroxysmal nocturnal hemoglobinuria. A spectrum from asymptomatic occlusion of hepatic venules to fatal Budd-Chiari syndrome.  Gastroenterology. 1987;  93 569-575
• 82 Miyakis S, Lockshin M D, Atsumi T et al.. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).  J Thromb Haemost. 2006;  4 295-306
• 83 Asherson R A, Khamashta M A, Ordi-Ros J et al.. The “primary” antiphospholipid syndrome; major clinical and serological features.  Medicine (Baltimore). 1989;  68 366-374
• 84 Alarcon-Segovia D, Deleze M, Oria C V, Sanchez-Guerrero J, Gomez-Pacheco L. Antiphospholipid antibodies and the antiphospholipid syndrome in SLE. A prospective analysis of 500 consecutive patients.  Medicine (Baltimore). 1989;  68 353-365
• 85 Triplett D A, Boffa M C. Lupus anticoagulant: detection, standardization and heterogeneity. In: Asherson RA, Cervera R, Piette J-C, Shoenfeld Y The Antiphospholipid Syndrome II. Autoimmune Thrombosis. Amsterdam; Elsevier 2002: 23-28
• 86 Pierangeli S S, Harris E N. Antibodies to cardiolipin and other phospholipids. In: Asherson RA, Cervera R, Piette J-C, Shoenfeld Y The Antiphospholipid Syndrome II. Autoimmune Thrombosis. Amsterdam; Elsevier 2002: 29-43
• 87 Galli M, Comfurius P, Maassen C et al.. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor.  Lancet. 1990;  335 1544-1547
• 88 McNeil H P, Simpson R J, Chesterman C N, Krilis S A. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: b2-glycoprotein I (apolipoprotein H).  Proc Natl Acad Sci U S A. 1990;  87 4120-4127
• 89 Matsuura E, Igarashi Y, Fujimoto M et al.. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease.  Lancet. 1990;  336 177-178
• 90 Bevers E M, Galli M, Barbui T, Comfurius P, Zwaal R FA. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin.  Thromb Haemost. 1991;  66 629-632
• 91 Galli M, Comfurius P, Barbui T, Zwaal R FA, Bevers E M. Anticoagulant activity of b2-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies.  Thromb Haemost. 1992;  68 297-300
• 92 Galli M, Beretta G, Daldossi M, Bevers E M, Barbui T. Different anticoagulant and immunological properties of antiprothrombin antibodies in patients with antiphospholipid antibodies.  Thromb Haemost. 1997;  77 486-491
• 93 Pelletier S, Landi B, Piette J C et al.. Antiphospholipid syndrome as the second cause of non-tumorous Budd-Chiari syndrome.  J Hepatol. 1994;  21(1) 76-80
• 94 Espinosa G, Font J, Garcia-Pagan J C et al.. Budd-Chiari syndrome secondary to antiphospholipid syndrome: clinical and immunologic characteristics of 43 patients.  Medicine (Baltimore). 2001;  80 345-354
• 95 Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis.  Thromb Haemost. 1999;  81 165-176
• 96 Li X M, Wei Y F, Hao H L et al.. Hyperhomocysteinemia and the MTHFR C677T mutation in Budd-Chiari syndrome.  Am J Hematol. 2002;  71(1) 11-14
• 97 Ray J G, Kearon C, Yi Q, Sheridan P, Lonn E. Homocysteine-lowering therapy and risk for venous thromboembolism: a randomized trial.  Ann Intern Med. 2007;  146 761-767